Studies of Psychiatric Predisposing Factors, Treatment-related Cardiovascular Effects, and Prognostic Factors Associated With Antimuscarinic Drug (Tolterodine) for Female Overactive Bladder Syndrome
NCT01503580 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 155
Last updated 2013-10-31
Summary
Overactive bladder syndrome (OAB) affects around 17 % of female population. However, the etiology of OAB was complicated and unclear in many aspects. In particular, the research about psychiatric aspect of etiology in OAB was paucity. Besides, research about prognostic factors and impact of cardiovascular system of OAB treatment was also paucity. Therefore the aims of the investigators study were (1) to analyze the etiology of OAB in psychiatric aspects; (2) to analyze the prognostic factors associated with tolterodine treatment; (3) to analyze the differences of cardiac conduction and heart rate variability before and after tolterodine treatment; (4) to analyze the differences of arterial stiffness between non-OAB and OAB female patients, and before and after tolterodine treatment.
Conditions
- Antimuscarinic Drug
Interventions
- DRUG
-
tolterodine, solifenacin
The enrolled women before March 2009 were treated with tolterodine 4 mg slow-release, and after March 2009 were treated with solifenacin 5 mg once a day for 12 weeks.
Sponsors & Collaborators
-
National Taiwan University Hospital
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2008-08-31
- Primary Completion
- 2010-07-31
- Completion
- 2013-10-31
Countries
- Taiwan
Study Locations
More Related Trials
-
Pharmacologic Effect for Female Overactive Bladder Syndrome: Mirabegron Versus Solifenacin
NCT04023253 ·Status: UNKNOWN ·Phase: PHASE3
-
Antimuscarinic Treatment for Female Patients With Overactive Bladder Syndrome: Comparison of Daytime and Nighttime Dosing
NCT01819168 ·Status: COMPLETED
-
Comparisons of the Impact of Monotherapy With Mirabegron or Tolterodine Versus Combined Treatment With Mirabegron and Tolterodine on Autonomic Function and Bladder Blow Flow in Women With Overactive Bladder Syndrome: a Randomized Controlled Study
NCT05946902 ·Status: UNKNOWN ·Phase: PHASE4
-
Risk Factors for Treatment Failure in Women With Detrusor Overactivity Receiving Combined Pharmacotherapy
NCT07337252 ·Status: COMPLETED
-
Comparisons of 3-month Versus 6-month Solifenacin Treatment for Female OAB Patients
NCT01876186 ·Status: UNKNOWN ·Phase: PHASE4
-
Prevalence and Risk Factors Nocturnal Polyuria in Female OAB
NCT03810027 ·Status: COMPLETED
-
The Effect of Nighttime Mirabegron, Solifenacin, Tolterodine, or Oxybutynin on Nocturia, Sexual Function, Autonomic Function, and Lower Urinary Tract Blood Flow Perfusion in Women With Overactive Bladder Syndrome: Randomized Controlled Trial
NCT07114640 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Comparisons of the Effects of Solifenacin Versus Mirabegron on Autonomic System, Arterial Stiffness and Psychosomatic Distress and Clinical Outcomes
NCT02540707 ·Status: COMPLETED ·Phase: PHASE4
-
Age-specific Prevalence and Comparisons of UDS and Bladder Diary Between OAB-wet and -Dry Women
NCT03807024 ·Status: COMPLETED
-
Tolterodine Drug Use Investigation.(Post Marketing Commitment Plan)
NCT01488578 ·Status: COMPLETED
-
Predictors for Retreatement of OAB After DC Mirabegron
NCT04550702 ·Status: COMPLETED
-
Interventional Clinical Trial in Patients in Overactive Bladder With Nocturia in Women
NCT01729819 ·Status: COMPLETED ·Phase: PHASE2
-
Sexual Function Trial of Overactive Bladder: Medication Versus PTNS
NCT03500146 ·Status: COMPLETED
-
Flexibly adding-on Second Antimuscarinic Agent to the First Antimuscarinics for Refractory Overactive Bladder Syndrome
NCT01824420 ·Status: COMPLETED ·Phase: PHASE4
-
Mirabegron for Female OAB Patients: Comparison of Daytime and Nighttime Dosing
NCT03251300 ·Status: UNKNOWN ·Phase: PHASE4
-
Effects of Antimuscarinic Drugs on Overactive Bladder (OAB) Symptoms After Insertion of Ureteral Stents
NCT01210859 ·Status: WITHDRAWN
-
Herbal Patch for Overactive Bladder
NCT03532789 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China
NCT03572231 ·Status: COMPLETED
-
A Therapeutic Exploratory Clinical Study of DA-8010 in Patients With Overactive Bladder
NCT03566134 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of beta3-adrenoceptor Agonist on Patients With Overactive Bladder and as a Urinary Biomarker
NCT04693897 ·Status: UNKNOWN
-
Evaluation of Adherence to Solifenacin Treatment in Overactive Bladder Patients
NCT00985387 ·Status: COMPLETED
-
SSR240600C Treatment in Women With Overactive Bladder
NCT00564226 ·Status: COMPLETED ·Phase: PHASE2
-
Therapeutic Efficacy and Safety of Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan
NCT03044912 ·Status: UNKNOWN ·Phase: PHASE3
-
Reproducibility Study of OABSS and Its Response to Treatment
NCT02667470 ·Status: COMPLETED ·Phase: PHASE4
-
The Effect of Anticholinergics on Cognitive Function in the Elderly
NCT01922115 ·Status: COMPLETED ·Phase: PHASE4